Click any tag below to further narrow down your results
Links
Anthropic has kicked off an internal drug discovery effort focused on neglected diseases to sharpen its AI tools for biopharma clients. By running its own research alongside partners, the company aims to gather feedback and demonstrate Claude Science’s capabilities.
- Anthropic is running its own internal drug discovery program targeting neglected diseases to battle-test and improve Claude Science before selling it to pharma partners.
- As a public benefit company, Anthropic claims it can choose projects based on patient need rather than commercial potential, unlike typical biotechs.
- The company hasn't said what happens if it finds a promising drug candidate, leaving unclear how it would handle clinical trials.
- This follows a mixed track record for big tech in healthcare, including Alphabet's life sciences unit, Apple's health features, and Amazon's One Medical/PillPack acquisitions.